Clinical Trial Update: Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 results for Boehringer Ingelheim's BILN-2061 ZW show antiviral activity, pharmacokinetics and safety data in patients with liver cirrhosis and chronic h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• BILN 2061 ZW (BILN-2061 ZW)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Liver Cirrhosis, Hepatitis C, Chronic | Phase 2 | Status: COMPLETED